RT journal article
T1 Growth hormone treatment does not to lead to insulin resistance nor excessive rise in IGF-1 levels, while improving height in patients small for gestational age A long-term observational study
A1 López‐Siguero, Juan P.
A1 Martínez‐Aedo, Maria J.
A1 Bermúdez de la Vega, José Antonio
A1 Bosch‐Muñoz, Jordi
A1 Lechuga Sancho, Alfonso María
A1 Villalobos, Triana
A1 SGA Study Investigator Collaborative Group
A2 Materno-Infantil y Radiología
K1 efficacy
K1 growth hormone
K1 homeostatic model assessment
K1 insulin resistance
K1 long‐term follow‐up
K1 safety
K1 small for gestational age
AB Objective In children born small for gestational age (SGA), the relationship between growth hormone (GH) treatment and insulin resistance (IR) has only been investigated for a short period, necessitating a longer observation period. This study aimed to evaluate the long-term (10 years) effect of GH to SGA-children on IR and safety during treatment. Design This was a multicenter observational study. Patients: SGA-children who received GH treatment in Spain (stratified by Tanner-stage and age at GH onset [two groups: <= 6 years old or >6 years old]). Measurements: The analysed variables (yearly measures) included auxologic, metabolic (insulin-like growth factor-1 (IGF-1), height velocity [HV], weight and homeostatic model assessment-IR [HOMA-IR]) and safety data. Data were collected prospectively (since the study approval: 2007) and retrospectively (since the initiation of GH treatment: 2005-2007). Results A total of 389 SGA children (369 Tanner-I) were recruited from 27 centres. The mean age (standard deviation) of the children at GH treatment onset was 7.2 (2.8) years old. IGF-1 (standard deviation score [SDS]) and HOMA-IR values tended to increase until the sixth year of GH-treatment, with significant differences being observed only during the first year, while these remained stable in the later years (within normal ranges). Height (SDS) increased significantly (basal: -3.0; tenth year: -1.13), and the maximum HV (SDS) occurred during the first year (2.75 +/- 2.39). Conclusions HOMA-IR values increased significantly in SGA-children during the first year of GH-treatment, remained stable and were within normal ranges in all cases. Our 10-year data suggests that long-term GH treatment does not promote IR and is well-tolerated, safe and effecti
PB WILEY
SN 0300-0664
YR 2021
FD 2021-12
LK http://hdl.handle.net/10498/26261
UL http://hdl.handle.net/10498/26261
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 11-nov-2026